AMPK-mediated regulation of neuronal metabolism and function in brain diseases

Journal of Neurogenetics

Volumn 29, Issue 2-3, 2015, Pages 50-58

  Liu, Yu Ju ^a   Chern, Yijuang ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Alzheimer ' s disease; AMPK; amyotrophic lateral sclerosis; brain; Huntington ' s disease; metformin

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; AMYLOID PRECURSOR PROTEIN; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; HOLOENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN KINASE LKB1; TAR DNA BINDING PROTEIN; TAU PROTEIN; ADENYLATE KINASE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELLULAR DISTRIBUTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEEDBACK SYSTEM; GENE OVEREXPRESSION; HUMAN; HUNTINGTON CHOREA; LONG TERM POTENTIATION; MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; BRAIN; BRAIN DISEASE; DEGENERATIVE DISEASE; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY;

ADENYLATE KINASE; BRAIN; BRAIN DISEASES; HUMANS; NEURODEGENERATIVE DISEASES; NEURONS;

EID: 84947032830     PISSN: 01677063     EISSN: 15635260     Source Type: Journal    
DOI: 10.3109/01677063.2015.1067203     Document Type: Review

References (123)

1. Abramov A. Y., Canevari L., &, Duchen M. R. (2004). Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. Biochim Biophys Acta, 1742, 81-87
2. Acevedo-Torres K., Berrios L., Rosario N., Dufault V., Skatchkov S., Eaton M. J., et al. (2009). Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair (Amst), 8, 126-136
3. Anderson K. A., Ribar T. J., Lin F., Noeldner P. K., Green M. F., Muehlbauer M. J., et al. (2008). Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab, 7, 377-388
4. Barber S. C., &, Shaw P. J. (2010). Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med, 48, 629-641
5. Bateman R. (2015). Alzheimer's disease and other dementias: advances in 2014. Lancet Neurol, 14, 4-6
6. Beretta S., Sala G., Mattavelli L., Ceresa C., Casciati A., Ferri A., et al. (2003). Mitochondrial dysfunction due to mutant copper/zinc superoxide dismutase associated with amyotrophic lateral sclerosis is reversed by N-Acetylcysteine. Neurobiol Dis, 13, 213-221
7. Browne S. E. (2008). Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci, 1147, 358-382
8. Browne S. E., Bowling A. C., Baik M. J., Gurney M., Brown R. H., Jr,. &, Beal M. F. (1998). Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J Neurochem, 71, 281-287
9. Cadenas E., &, Davies K. J. (2000). Mitochondrial free radical generation, oxidative stress, and aging. Free Radic Biol Med, 29, 222-230
10. Calkins M. J., Manczak M., Mao P., Shirendeb U., &, Reddy P. H. (2011a). Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Hum Mol Genet, 20, 4515-4529
11. Calkins M. J., &, Reddy P. H. (2011b). Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage. Biochim Biophys Acta, 1812, 1182-1189
12. Canobbio I., Abubaker A. A., Visconte C., Torti M., &, Pula G. (2015). Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's disease. Front Cell Neurosci, 9, 65
13. Caspersen C., Wang N., Yao J., Sosunov A., Chen X., Lustbader J. W., et al. (2005). Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J, 19, 2040-2041
14. Chang D. T., Rintoul G. L., Pandipati S., &, Reynolds I. J. (2006). Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis, 22, 388-400
15. Chaturvedi R. K., Calingasan N. Y., Yang L., Hennessey T., Johri A., &, Beal M. F. (2010). Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum Mol Genet, 19, 3190-3205
16. Chaturvedi R. K., &, Flint Beal M. (2013). Mitochondrial diseases of the brain. Free Radic Biol Med, 63, 1-29
17. Chen M., Wang Z., Zhan M., Liu R., Nie A., Wang J., et al. (2014). Adiponectin regulates ACTH secretion and the HPAA in an AMPK-dependent manner in pituitary corticotroph cells. Mol Cell Endocrinol, 383, 118-125
18. Chen Y., Zhou K., Wang R., Liu Y., Kwak Y. D., Ma T., et al. (2009). Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci U S A, 106, 3907-3912
19. Chikahisa S., Fujiki N., Kitaoka K., Shimizu N., &, Sei H. (2009). Central AMPK contributes to sleep homeostasis in mice. Neuropharmacol, 57, 369-374
20. Choi J.S., Park C., &, Jeong J.W. (2010). AMP-Activated protein kinase is activated in Parkinson's disease models mediated by 1-methyl-4-phenyl-1,2,3,6-Tetrahydropyridine. Biochem Biophys Res Commun, 391, 147-151
21. Choi S. L., Kim S. J., Lee K.T., Kim J., Mu J., Birnbaum M. J., et al. (2001). The regulation of AMP-Activated protein kinase by H(2)O(2). Biochem Biophys Res Commun, 287, 92-97
22. Chou S. Y., Lee Y. C., Chen H. M., Chiang M. C., Lai H. L., Chang H. H., et al. (2005). CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model. J Neurochem, 93, 310-320
23. Costa V., Giacomello M., Hudec R., Lopreiato R., Ermak G., Lim D., et al. (2010). Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol Med, 2, 490-503
24. Coughlan K. S., Mitchem M. R., Hogg M. C., &, Prehn J. H. (2015). "Preconditioning" with latrepirdine, an adenosine 5′-monophosphate-Activated protein kinase activator, delays amyotrophic lateral sclerosis progression in SOD1(G93A) mice. Neurobiol Aging, 36, 1140-1150
25. Coussee E., De Smet P., Bogaert E., Elens I., Van Damme P., Willems P., et al. (2011). G37R SOD1 mutant alters mitochondrial complex I activity, Ca(2+) uptake and ATP production. Cell Calcium, 49, 217-225
26. Dagon Y., Hur E., Zheng B., Wellenstein K., Cantley L. C., &, Kahn B. B. (2012). p70S6 kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake. Cell metabol, 16, 104-112
27. Damiano M., Starkov A. A., Petri S., Kipiani K., Kiaei M., Mattiazzi M., et al. (2006). Neural mitochondrial Ca2 + capacity impairment precedes the onset of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J Neurochem, 96, 1349-1361
28. DiTacchio K. A., Heinemann S. F., &, Dziewczapolski G. (2015). Metformin treatment alters memory function in a mouse model of Alzheimer's disease. J Alzheimers Dis, 44, 43-48
29. Djouder N., Tuerk R. D., Suter M., Salvioni P., Thali R. F., Scholz R., et al. (2010). PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. The EMBO journal, 29, 469-481
30. Du H., Guo L., Yan S., Sosunov A. A., Mckhann G. M., &, Yan S. S. (2010). Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A, 107, 18670-18675
31. Farkas M. E., Li B. C., Dose C., &, Dervan P. B. (2009). DNA sequence selectivity of hairpin polyamide turn units. Bioorg Med Chem Lett, 19, 3919-3923
32. Federico A., Cardaioli E., Da Pozzo P., Formichi P., Gallus G. N., &, Radi E. (2012). Mitochondria, oxidative stress and neurodegeneration. J Neurol Sci, 322, 254-262
33. Ferreira I. L., Nascimento M. V., Ribeiro M., Almeida S., Cardoso S. M., Grazina M., et al. (2010). Mitochondrial-dependent apoptosis in Huntington's disease human cybrids. Exp Neurol, 222, 243-255
34. Fogarty S., &, Hardie D. G. (2010). Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta, 1804, 581-591
35. Fryer L. G., Parbu-Patel A., &, Carling D. (2002). The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-Activated protein kinase through distinct signaling pathways. J Biol Chem, 277, 25226-25232
36. Georgiou-Karistianis N., Scahill R., Tabrizi S. J., Squitieri F., &, Aylward E. (2013). Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev, 37, 480-490
37. Goodman M., Liu Z., Zhu P., &, Li J. (2014). AMPK Activators as a Drug for Diabetes, Cancer and Cardiovascular Disease. Pharmaceut Reg Affairs, 3, 1000118
38. Goswami A., Dikshit P., Mishra A., Mulherkar S., Nukina N., &, Jana N.R. (2006). Oxidative stress promotes mutant huntingtin aggregation and mutant huntingtin-dependent cell death by mimicking proteasomal malfunction. Biochem Biophys Res Commun, 342, 184-190
39. Greco S. J., Hamzelou A., Johnston J. M., Smith M. A., Ashford J. W., &, Tezapsidis N. (2011). Leptin boosts cellular metabolism by activating AMPK and the sirtuins to reduce tau phosphorylation and beta-Amyloid in neurons. Biochem Biophys Res Commun, 414, 170-174
40. Greco S. J., Sarkar S., Johnston J. M., &, Tezapsidis N. (2009). Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun, 380, 98-104
41. Guo X., Disatnik M. H., Monbureau M., Shamloo M., Mochly-Rosen D., &, Qi X. (2013). Inhibition of mitochondrial fragmentation diminishes Huntington's disease-Associated neurodegeneration. J Clin Invest, 123, 5371-5388
42. Gurney M. E., Pu H., Chiu A. Y., Dal Canto M. C., Polchow C. Y., Alexander D. D., et al. (1994). Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 264, 1772-1775
43. Hardie D. G. (2007). AMP-Activated protein kinase as a drug target. Ann Rev Pharmacol Toxicol, 47, 185-210
44. Hardie D. G. (2008). AMPK: a key regulator of energy balance in the single cell and the whole organism. Int J Obesity, 32 Suppl 4, S7-12
45. Hardie D. G., Ross F. A., &, Hawley S. A. (2012). AMP-Activated protein kinase: a target for drugs both ancient and modern. Chem Biol, 19, 1222-1236
46. Hawley S. A., Pan D. A., Mustard K. J., Ross L., Bain J., Edelman A. M., et al. (2005). Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-Activated protein kinase. Cell Metabol, 2, 9-19
47. Heneka M. T., Carson M. J., Khoury J. E., Landreth G. E., Brosseron F., Feinstein D. L., et al. (2015a). Neuroinflammation in Alzheimer's disease. Lancet Neurol, 14, 388-405
48. Heneka M. T., Golenbock D. T., &, Latz E. (2015b). Innate immunity in Alzheimer's disease. Nat Immunol, 16, 229-236
49. Horie T., Ono K., Nagao K., Nishi H., Kinoshita M., Kawamura T., et al. (2008). Oxidative stress induces GLUT4 translocation by activation of PI3-K/Akt and dual AMPK kinase in cardiac myocytes. J Cell Physiol, 215, 733-742
50. Horvath T. L., Erion D. M., Elsworth J. D., Roth R. H., Shulman G. I., &, Andrews Z. B. (2011). GPA protects the nigrostriatal dopamine system by enhancing mitochondrial function. Neurobiol Dis, 43, 152-162
51. Hunter R. W., Foretz M., Bultot L., Fullerton M. D., Deak M., Ross F. A., et al. (2014). Mechanism of action of compound-13: an alpha1-selective small molecule activator of AMPK. Chem Biol, 21, 866-879
52. Hurley R. L., Barre L. K., Wood S. D., Anderson K. A., Kemp B. E., Means A. R., et al. (2006). Regulation of AMP-Activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. J Biol Chem, 281, 36662-36672
53. Janssens J., &, Van Broeckhoven C. (2013). Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders. Hum Mol Genet, 22, R77-87
54. Jiang T., Yu J. T., Zhu X. C., Zhang Q. Q., Tan M. S., Cao L., et al. (2015). Ischemic preconditioning provides neuroprotection by induction of AMP-Activated protein kinase-dependent autophagy in a rat model of ischemic stroke. Mol Neurobiol, 51, 220-229
55. Johri A., Chaturvedi R. K., &, Beal M. F. (2011). Hugging tight in Huntington's. Nat Med, 17, 245-246
56. Ju T. C., Chen H. M., Chen Y. C., Chang C. P., Chang C., &, Chern Y. (2014). AMPK-Alpha1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease. Biochim Biophys Acta, 1842, 1668-1680
57. Ju T. C., Chen H. M., Lin J. T., Chang C. P., Chang W. C., Kang J. J., et al. (2011). Nuclear translocation of AMPK-Alpha1 potentiates striatal neurodegeneration in Huntington's disease. J Cell Biol, 194, 209-227
58. Ju T. C., Lin Y. S., &, Chern Y. (2012). Energy dysfunction in Huntington's disease: insights from PGC-1alpha, AMPK, and CKB. Cell Mol Life Sci, 69, 4107-4120
59. Ju T. C,., Liu Y. J,., Chen Y.-C,., Chen H.-M,. &, Chern Y. (2015). Feedback regulation between AMPK and ATM in Huntington's disease. Biochim Biophys Acta, 1842, 1668-1680
60. Kemp B. E., Mitchelhill K. I., Stapleton D., Michell B. J., Chen Z. P., &, Witters L. A. (1999). Dealing with energy demand: the AMP-Activated protein kinase. Trends Biochem Sci, 24, 22-25
61. Kirby J., Menzies F. M., Cookson M. R., Bushby K., &, Shaw P. J. (2002). Differential gene expression in a cell culture model of SOD1-related familial motor neurone disease. Hum Mol Genet, 11, 2061-2075
62. Kirkinezos I. G., Bacman S. R., Hernandez D., Oca-Cossio J., Arias L. J., Perez-Pinzon M. A., et al. (2005). Cytochrome c association with the inner mitochondrial membrane is impaired in the CNS of G93A-SOD1 mice. J Neurosci, 25, 164-172
63. Labbadia J., &, Morimoto R. I. (2013). Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci, 38, 378-385
64. Lage R., Dieguez C., Vidal-Puig A., &, Lopez M. (2008). AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med, 14, 539-549
65. Lee J. Y., Jeon B. T., Shin H. J., Lee D. H., Han J. Y., Kim H. J., et al. (2009). Temporal expression of AMP-Activated protein kinase activation during the kainic acid-induced hippocampal cell death. J Neural Trans, 116, 33-40
66. Li J., Benashski S. E., Siegel C., Liu F., &, Mccullough L. D. (2010a). Adenosine monophosphate activated protein kinase inhibition is protective in both sexes after experimental stroke. Neurosci Lett, 482, 62-65
67. Li J., Benashski S. E., Venna V. R., &, Mccullough L. D. (2010b). Effects of metformin in experimental stroke. Stroke, 41, 2645-2652
68. Li J., Zeng Z., Viollet B., Ronnett G. V., &, Mccullough L. D. (2007). Neuroprotective effects of adenosine monophosphate-Activated protein kinase inhibition and gene deletion in stroke. Stroke, 38, 2992-2999
69. Lim D., Fedrizzi L., Tartari M., Zuccato C., Cattaneo E., Brini M., et al. (2008). Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem, 283, 5780-5789
70. Lim M. A., Selak M. A., Xiang Z., Krainc D., Neve R. L., Kraemer B. C., et al. (2012). Reduced activity of AMP-Activated protein kinase protects against genetic models of motor neuron disease. J Neurosci, 32, 1123-1141
71. Ling S. C., Albuquerque C. P., Han J. S., Lagier-Tourenne C., Tokunaga S., Zhou H., et al. (2010). ALS-Associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A, 107, 13318-13323
72. Liu F., Benashski S. E., Persky R., Xu Y., Li J., &, Mccullough L. D. (2012). Age-related changes in AMP-Activated protein kinase after stroke. Age, 34, 157-168
73. Liu Y. J., Ju T. C., Chen H. M., Jang Y. S., Lee L. M., Lai H. L., et al. (2015a). Activation of AMP-Activated protein kinase alpha1 mediates mislocalization of TDP-43 in amyotrophic lateral sclerosis. Hum Mol Genet, 24, 787-801
74. Liu Y. J., Lee L. M., Lai H. L., &, Chern Y. (2015b). Aberrant activation of AMP-Activated protein kinase contributes to the abnormal distribution of HuR in amyotrophic lateral sclerosis. FEBS Lett
75. Long Y. C., &, Zierath J. R. (2006). AMP-Activated protein kinase signaling in metabolic regulation. J Clin Invest, 116, 1776-1783
76. Ma T., Chen Y., Vingtdeux V., Zhao H., Viollet B., Marambaud P., et al. (2014). Inhibition of AMP-Activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid beta. J Neurosci, 34, 12230-12238
77. Mairet-Coello G., Courchet J., Pieraut S., Courchet V., Maximov A., &, Polleux F. (2013). The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Abeta oligomers through Tau phosphorylation. Neuron, 78, 94-108
78. Manczak M., Anekonda T. S., Henson E., Park B. S., Quinn J., &, Reddy P. H. (2006). Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet, 15, 1437-1449
79. Manczak M., Calkins M. J., &, Reddy P. H. (2011). Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet, 20, 2495-2509
80. Martinez De Morentin P. B., Gonzalez-Garcia I., Martins L., Lage R., Fernandez-Mallo D., Martinez-Sanchez N., et al. (2014). Estradiol regulates brown adipose tissue thermogenesis via hypothalamic AMPK. Cell metabolism, 20, 41-53
81. Mattiazzi M., D'aurelio M., Gajewski C. D., Martushova K., Kiaei M., Beal M. F., et al. (2002). Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem, 277, 29626-29633
82. McCullough L. D., Zeng Z., Li H., Landree L. E., Mcfadden J., &, Ronnett G. V. (2005). Pharmacological inhibition of AMP-Activated protein kinase provides neuroprotection in stroke. J Biol Chem, 280, 20493-20502
83. Menzies F. M., Cookson M. R., Taylor R. W., Turnbull D. M., Chrzanowska-Lightowlers Z. M., Dong L., et al. (2002). Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain, 125, 1522-1533
84. Muller F. L., Lustgarten M. S., Jang Y., Richardson A., &, Van Remmen H. (2007). Trends in oxidative aging theories. Free Radic Biol Med, 43, 477-503
85. Oliveira J. M., Chen S., Almeida S., Riley R., Goncalves J., Oliveira C. R., et al. (2006). Mitochondrial-dependent Ca2 + handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci, 26, 11174-11186
86. Panov A. V., Gutekunst C. A., Leavitt B. R., Hayden M. R., Burke J. R., Strittmatter W. J., et al. (2002). Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci, 5, 731-736
87. Panov A. V., Lund S., &, Greenamyre J. T. (2005). Ca2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem, 269, 143-152
88. Park H., Kam T. I., Kim Y., Choi H., Gwon Y., Kim C., et al. (2012). Neuropathogenic role of adenylate kinase-1 in Abeta-mediated tau phosphorylation via AMPK and GSK3beta. Hum Mol Genet, 21, 2725-2737
89. Pavlov P. F., Hansson Petersen C., Glaser E., &, Ankarcrona M. (2009). Mitochondrial accumulation of APP and Abeta: significance for Alzheimer disease pathogenesis. J Cell Mol Med, 13, 4137-4145
90. Perera N. D., Sheean R. K., Scott J. W., Kemp B. E., Horne M. K., &, Turner B. J. (2014). Mutant TDP-43 deregulates AMPK activation by PP2A in ALS models. PLoS One, 9, e95549
91. Pimentel C., Batista-Nascimento L., Rodrigues-Pousada C., &, Menezes R. A. (2012). Oxidative stress in Alzheimer's and Parkinson's diseases: insights from the yeast Saccharomyces cerevisiae. Oxid Med Cell Longev, 2012, 132146
92. Powers W. J., Videen T. O., Markham J., Mcgee-Minnich L., Antenor-Dorsey J. V., Hershey T., et al. (2007). Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc Natl Acad Sci U S A, 104, 2945-2949
93. Querfurth H. W., &, LaFerla F. M. (2010). Alzheimer's disease. N Engl J Med, 362, 329-344
94. Reilmann R. (2013). Pharmacological treatment of chorea in Huntington's disease-good clinical practice versus evidence-based guideline. Mov Disord, 28, 1030-1033
95. Salt I., Celler J. W., Hawley S. A., Prescott A., Woods A., Carling D., et al. (1998). AMP-Activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J, 334 (Pt 1), 177-187
96. Santos R. X., Correia S. C., Wang X., Perry G., Smith M. A., Moreira P. I., et al. (2010). A synergistic dysfunction of mitochondrial fission/fusion dynamics and mitophagy in Alzheimer's disease. J Alzheimers Dis, 20 Suppl 2, S401-412
97. Sasaki S., Warita H., Murakami T., Abe K., &, Iwata M. (2004). Ultrastructural study of mitochondria in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol, 107, 461-474
98. Seo K., Ki S. H., &, Shin S. M. (2015). Sestrin2-AMPK activation protects mitochondrial function against glucose deprivation-induced cytotoxicity. Cellular signalling
99. She P., Zhang Z., Marchionini D., Diaz W. C., Jetton T. J., Kimball S. R., et al. (2011). Molecular characterization of skeletal muscle atrophy in the R6/2 mouse model of Huntington's disease. Am J Physiol Endocrinol Metab, 301, E49-61
100. Shimohama S., Tanino H., Kawakami N., Okamura N., Kodama H., Yamaguchi T., et al. (2000). Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun, 273, 5-9
101. Solans A., Zambrano A., Rodriguez M., &, Barrientos A. (2006). Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III. Hum Mol Genet, 15, 3063-3081
102. Son S. M., Jung E. S., Shin H. J., Byun J., &, Mook-Jung I. (2012). Abeta-induced formation of autophagosomes is mediated by RAGE-CaMKKbeta-AMPK signaling. Neurobiol Aging, 33, 1006 e1011-1023
103. Steinberg G. R., Dandapani M., &, Hardie D. G. (2013). AMPK: mediating the metabolic effects of salicylate-based drugs? Trends Endocrinol Metabol, 24, 481-487
104. Suzuki A., Okamoto S., Lee S., Saito K., Shiuchi T., &, Minokoshi Y. (2007). Leptin stimulates fatty acid oxidation and peroxisome proliferator-Activated receptor alpha gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the alpha2 form of AMP-Activated protein kinase. Mol Cell Biol 27, 4317-4327
105. Thornton C., Bright N. J., Sastre M., Muckett P. J., &, Carling D. (2011). AMP-Activated protein kinase (AMPK) is a tau kinase, activated in response to amyloid beta-peptide exposure. Biochem J, 434, 503-512
106. Thornton C., Snowden M. A., &, Carling D. (1998). Identification of a novel AMP-Activated protein kinase beta subunit isoform that is highly expressed in skeletal muscle. J Biol Chem, 273, 12443-12450
107. Tsai K. J., Yang C. H., Fang Y. H., Cho K. H., Chien W. L., Wang W. T., et al. (2010). Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med, 207, 1661-1673
108. Turnley A. M., Stapleton D., Mann R. J., Witters L. A., Kemp B. E., &, Bartlett P. F. (1999). Cellular distribution and developmental expression of AMP-Activated protein kinase isoforms in mouse central nervous system. J Neurochem, 72, 1707-1716
109. Venna V. R., Li J., Hammond M. D., Mancini N. S., &, Mccullough L. D. (2014). Chronic metformin treatment improves post-stroke angiogenesis and recovery after experimental stroke. Eur J Neurosci, 39, 2129-2138
110. Vingtdeux V., Davies P., Dickson D. W., &, Marambaud P. (2011). AMPK is abnormally activated in tangle-And pre-Tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol, 121, 337-349
111. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J. E., et al. (2010). AMP-Activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem, 285, 9100-9113
112. Wang H., Lim P. J., Karbowski M., &, Monteiro M. J. (2009). Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet, 18, 737-752
113. Wang Z. G., Yang C., Zhu B., &, Hua F. (2015). AMPK-Dependent Autophagic Activation Is Probably Involved in the Mechanism of Resveratrol Exerting Therapeutic Effects for Alzheimer's Disease. Rejuven Res, 18, 101-102
114. Weisova P., Concannon C. G., Devocelle M., Prehn J.H., &, Ward M. W. (2009). Regulation of glucose transporter 3 surface expression by the AMP-Activated protein kinase mediates tolerance to glutamate excitation in neurons. J Neurosci, 29, 2997-3008
115. Woods A., Dickerson K., Heath R., Hong S. P., Momcilovic M., Johnstone S. R., et al. (2005). Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-Activated protein kinase in mammalian cells. Cell Metabol, 2, 21-33
116. Wu S. B., Wu Y. T., Wu T. P., &, Wei Y. H. (2014). Role of AMPK-mediated adaptive responses in human cells with mitochondrial dysfunction to oxidative stress. Biochim Biophys Acta, 1840, 1331-1344
117. Xiao B., Sanders M. J., Carmena D., Bright N. J., Haire L. F., Underwood E., et al. (2013). Structural basis of AMPK regulation by small molecule activators. Nat Commun, 4, 3017
118. Xu Y. F., Gendron T. F., Zhang Y. J., Lin W. L., D'alton S., Sheng H., et al. (2010). Wild-Type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice. J Neurosci, 30, 10851-10859
119. Xu Y. F., Zhang Y. J., Lin W. L., Cao X., Stetler C., Dickson D. W., et al. (2011). Expression of mutant TDP-43 induces neuronal dysfunction in transgenic mice. Mol Neurodegener, 6, 73
120. Yoon S. O., Park D. J., Ryu J. C., Ozer H. G., Tep C., Shin Y. J., et al. (2012). JNK3 perpetuates metabolic stress induced by Abeta peptides. Neuron, 75, 824-837
121. Zadra G., Photopoulos C., Tyekucheva S., Heidari P., Weng Q. P., Fedele G., et al. (2014). A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis. EMBO Mol Med, 6, 519-538
122. Zhao Z., Sui Y., Gao W., Cai B., &, Fan D. (2015). Effects of diet on adenosine monophosphate-Activated protein kinase activity and disease progression in an amyotrophic lateral sclerosis model. J Int Med Res, 43, 67-79
123. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., et al. (2001). Role of AMP-Activated protein kinase in mechanism of metformin action. J Clin Invest, 108, 1167-1174